BIMINI Biotech is happy to have Prof. Nathaniel Martin join the team as an advisor on chemistry, supporting the lead optimization. Prof. Martin is Professor of Biological Chemistry Institute of Biology Leiden (IBL) Leiden. He obtained his PhD degree from the University of Alberta in 2004. He subsequently performed postdoctoral studies at the University of…
Lees meer
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer
Leiden, 29 June 2023 – BIMINI Biotech, an innovative Leiden-based therapeutics start-up that develops novel therapeutics for hematological cancers, raised an additional investment of €250,000 from lead investor Libertatis Ergo Holding B.V. (LEH). The investment will be used in combination with a recently awarded Eurostars grant to progress the preclinical development of our lead candidates…
Lees meer
Leiden, 1 April 2023 – BIMINI Biotech, an innovative therapeutics startup, was recently awarded a Eureka Eurostars project with the aim of developing novel therapeutics for lymphomas. This project named HEMATO-WASP, brings together a unique consortium consisting of BIMINI Biotech (Leiden, the Netherlands), InnoSer Nederland (Leiden, the Netherlands) and the Institute of Oncology Research (IOR;…
Lees meer
Compound BM-011 (also known as EG-011) has been selected as molecule of the month November 2022 by Drug Hunter. Drug Hunter™ is an essential resource for the community of R&D innovators turning molecules into medicines. Drug Hunter distills the science behind emerging drugs and technologies into an easy-to-read and simple-to-search reference. Drug Hunter identified the…
Lees meer
Leiden, 19 January 2023 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has signed an exclusive license agreement with the Institute of Oncology Research (IOR) to acquire and further develop a novel first-in-class Wiskott Aldrich Syndrome protein (WASp) activator. The company aims to leverage WASp modulation to target hematological cancers. The…
Lees meer
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the MCL-TX project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer
BIMINI Biotech was recently awarded a Eureka Eurostars project with the aim of targeting the growth hormone receptor for novel and personalized cancer therapeutics. This project named ONCO-TARGET, brings together a unique consortium consisting of BIMINI Biotech (drug development), Specs Compound Handling (chemistry), Uppsala University (oncology and genetics) and IVRS (pre-clinical in vivo modelling), with…
Lees meer
Leiden, 15 October 2021 – BIMINI Biotech, an innovative therapeutics start-up that develops new cancer drugs, raised an investment of €250,000. The seed funding is provided by Libertatis Ergo Holding B.V. (LEH), a wholly owned subsidiary of Leiden University which supports and invests in spinout companies associated with Leiden University’s activities. BIMINI Biotech will leverage…
Lees meer
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the ONCO-ID project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer